Iron chelation therapy with deferoxamine in Cooley anemia.
Iron chelation therapy with deferoxamine in Cooley anemia.
复制标题
用去铁胺进行铁螯合治疗库利贫血。
DOI：
10.1016/s0022-3476(78)80314-x
复制
发表时间：
1978
期刊：
影响因子：
--
通讯作者：
E. Schwartz
中科院分区：
文献类型：
--
作者：
A. Cohen;E. Schwartz
铁螯合剂去铁胺在16例重度地中海贫血患者中的应用研究。肌肉注射0.75克去铁胺后，尿中铁的排泄量为2.2至44.8 mg /24小时。皮下输注1.5克去铁胺18小时后，铁排泄量平均增加240%。静脉输注大剂量去铁胺18小时，铁排泄率最高，在16克去铁胺的反应下，铁排泄率高达447.5 mg /24小时。大多数5岁以上患者服用维生素C可增加螯合诱导的铁排泄。初步证据表明，可以通过肌肉、皮下或静脉给药去铁胺来防止进一步的铁积累，并减少过量的铁储存。
The iron-chelating agent, deferoxamine, was studied in 16 patients with thalassemia major. Urinary excretion of iron in response to 0.75 gm of deferoxamine, intramuscularly, ranged from 2.2 to 44.8 mg Fe/24 hours. In response to a subcutaneous infusion of 1.5 gm deferoxamine for 18 hours, iron excretion increased by an average of 240%. The intravenous infusion of large doses of deferoxamine for 18 hours resulted in the highest rate of iront excretion, as much as 447.5 mg Fe/24 hours in response to 16 gm of deferoxamine. Administration of vitamin C increased chelation-induced excretion of iron in most patients more than five years of age. Preliminary evidence suggests that further iron accumulation can be prevented and exessive iron stores can be depleted by the intramuscular, subcutaneous, or intravenous administration of deferoxamine.